Connor Prosty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Connor Prosty has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
Moshe Ben-Shoshan
Division of Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada
11 shared publicationsXun Zhang
McGill University
10 shared publications- Elena Netchiporouk
Division of Dermatology, Department of Medicine McGill University and McGill University Health Centre Montreal Quebec Canada
9 shared publications - Emily Gibson McDonald
Division of Experimental Medicine, Department of Medicine, McGill University , Montreal, Quebec
9 shared publications Todd C. Lee
Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada
9 shared publications- Sofianne Gabrielli
Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada
8 shared publications
Latest Publications
- Open Access
Effect of Proton Pump Inhibitor Deprescription on the Risk of Clostridioides difficile Infection: A Quasi-Interventional Substudy of MedSafer
Background: Proton pump inhibitors (PPIs) have been proposed as a risk factor for initial and recurrent Clostridioides difficile infection (CDI) based on observational data. Whether desprescribing PPIs reduces the odds of incident CDI is unknown. Methods: This was a secondary analysis of the cluster randomized MedSafer clinical trial dataset, in which hospitalized older adults taking five or more medications were randomized to usual care (a medication review) or electronic deprescribing decision support prior to hospital discharge. For this substudy, all patients were included regardless of trial assignment and were categorized according to their PPI use at hospitalization and discharge. The 30-day occurrence of CDI was compared as a function of PPI use using a Bayesian mixed-effect logistic regression adjusted for prespecified confounders. Results: 4990 patients were included in the analysis, including 405 (8.1%) patients who were deprescribed their home PPI and 325 (6.5%) new PPI users. 30-day CDI occurred in 32 (0.6%) patients. PPI deprescription was associated with a 99.1% probability of increased odds of CDI (adjusted odds ratio[aOR]=3.66, 95%Credible interval[95%CrI]=1.25-10.11). New PPI use, however, was not associated with a probable increase in CDI (aOR=1.14, 95%CrI=0.20-4.67). Conclusion: Unexpectedly, PPI deprescription was associated with a higher odds of CDI. This challenges the practice of deprescribing unnecessary PPIs in hospitalized patients for CDI prevention. However, it is possible this finding is artefactual due to confounding by indication. Further mechanistic and confirmatory studies are needed. SOCIAL MEDIA POST: In a secondary analysis of a recent deprescribing software trial, proton pump inhibitor deprescription but not new use increased the odds of 30-day Clostridioides difficile .
Open AccessEffect of Proton Pump Inhibitor Deprescription on the Risk of Clostridioides difficile Infection: A Quasi-Interventional Substudy of MedSafer
Background: Proton pump inhibitors (PPIs) have been proposed as a risk factor for initial and recurrent Clostridioides difficile infection (CDI) based on observational data. Whether desprescribing PPIs reduces the odds of incident CDI is unknown. Methods: This was a secondary analysis of the cluster randomized MedSafer clinical trial dataset, in which hospitalized older adults taking five or more medications were randomized to usual care (a medication review) or electronic deprescribing decision support prior to hospital discharge. For this substudy, all patients were included regardless of trial assignment and were categorized according to their PPI use at hospitalization and discharge. The 30-day occurrence of CDI was compared as a function of PPI use using a Bayesian mixed-effect logistic regression adjusted for prespecified confounders. Results: 4990 patients were included in the analysis, including 405 (8.1%) patients who were deprescribed their home PPI and 325 (6.5%) new PPI users. 30-day CDI occurred in 32 (0.6%) patients. PPI deprescription was associated with a 99.1% probability of increased odds of CDI (adjusted odds ratio[aOR]=3.66, 95%Credible interval[95%CrI]=1.25-10.11). New PPI use, however, was not associated with a probable increase in CDI (aOR=1.14, 95%CrI=0.20-4.67). Conclusion: Unexpectedly, PPI deprescription was associated with a higher odds of CDI. This challenges the practice of deprescribing unnecessary PPIs in hospitalized patients for CDI prevention. However, it is possible this finding is artefactual due to confounding by indication. Further mechanistic and confirmatory studies are needed. SOCIAL MEDIA POST: In a secondary analysis of a recent deprescribing software trial, proton pump inhibitor deprescription but not new use increased the odds of 30-day Clostridioides difficile .
- Open Access
Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Background The optimal treatment for first episodes and first recurrences of Clostridioides difficile infections (CDI) is unknown and there is emerging evidence for pulse-and-taper (P-T) regimens. Therefore, we sought to estimate the relative efficacy of treatment options. Methods MEDLINE and CENTRAL were searched from database inception to September 11, 2026. Randomized controlled trials (RCTs) on the treatment of first episodes or first recurrences of CDI comparing fixed-dose or P-T regimens of fidaxomicin or vancomycin were included. The primary and secondary outcomes were 40- and 56-day CDI recurrence, respectively. A random-effects network meta-analysis on the risk ratio (RR) scale was conducted using a standard regimen (10-14 days) of vancomycin as the comparator. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Results 8 RCTs were included, comprising 2120 patients. For 40-day recurrence, fidaxomicin P-T had the highest probability of ranking best (RR=0.10, 95%Confidence Interval [95%CI]=0.03-0.33, SUCRA=0.99), followed by vancomycin P-T (RR=0.40, 95%CI=0.25-0.63, SUCRA=0.66), fixed-dose fidaxomicin (RR=0.63, 95%CI=0.51-0.78, SUCRA=0.34), and, finally, fixed-dose of vancomycin (SUCRA=0.00). The treatments ranked in the same order for 56-day recurrence, though only 3 RCTs reported on this timepoint and fixed-dose fidaxomicin was no longer significantly better than fixed-dose vancomycin. Conclusion Fidaxomicin P-T and vancomycin P-T were both superior to fixed-dose vancomycin at 40- and 56-days. Head-to-head comparative effectiveness RCTs are needed to quantify their relative effect sizes of and impact on long-term prevention of recurrent CDI.
Open AccessComparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Background The optimal treatment for first episodes and first recurrences of Clostridioides difficile infections (CDI) is unknown and there is emerging evidence for pulse-and-taper (P-T) regimens. Therefore, we sought to estimate the relative efficacy of treatment options. Methods MEDLINE and CENTRAL were searched from database inception to September 11, 2026. Randomized controlled trials (RCTs) on the treatment of first episodes or first recurrences of CDI comparing fixed-dose or P-T regimens of fidaxomicin or vancomycin were included. The primary and secondary outcomes were 40- and 56-day CDI recurrence, respectively. A random-effects network meta-analysis on the risk ratio (RR) scale was conducted using a standard regimen (10-14 days) of vancomycin as the comparator. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Results 8 RCTs were included, comprising 2120 patients. For 40-day recurrence, fidaxomicin P-T had the highest probability of ranking best (RR=0.10, 95%Confidence Interval [95%CI]=0.03-0.33, SUCRA=0.99), followed by vancomycin P-T (RR=0.40, 95%CI=0.25-0.63, SUCRA=0.66), fixed-dose fidaxomicin (RR=0.63, 95%CI=0.51-0.78, SUCRA=0.34), and, finally, fixed-dose of vancomycin (SUCRA=0.00). The treatments ranked in the same order for 56-day recurrence, though only 3 RCTs reported on this timepoint and fixed-dose fidaxomicin was no longer significantly better than fixed-dose vancomycin. Conclusion Fidaxomicin P-T and vancomycin P-T were both superior to fixed-dose vancomycin at 40- and 56-days. Head-to-head comparative effectiveness RCTs are needed to quantify their relative effect sizes of and impact on long-term prevention of recurrent CDI.
- Open Access
- 9 July 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial
Clostridioides difficile infection (CDI) is a prevalent, morbid, and expensive disease that recurs in approximately 25% of patients despite treatment. Re-e
- 9 July 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessSecondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial
Clostridioides difficile infection (CDI) is a prevalent, morbid, and expensive disease that recurs in approximately 25% of patients despite treatment. Re-e
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (4)
Secondary vancomycin prophylaxis during antibiotic re-exposure for the prevention of recurrent Clostridioides difficile infections: a systematic review and Bayesian meta-analysis
Background: Antibiotic re-exposure after an episode of Clostridioides difficile infection (CDI) is common and is a strong risk factor for recurrent CDI (rCDI). Two randomized controlled trials (RCTs) of vancomycin prophylaxis during antibiotic re-exposure were recently published, which we sought to evaluate by meta-analysis. Methods: We updated a recent systematic review search of MEDLINE and Embase via Ovid to 9 March 2026. RCTs of vancomycin during antibiotic re-exposure as secondary CDI prophylaxis were included. Quality was assessed by the Cochrane RoB2 tool. A Bayesian meta-analysis of 56-day rCDI was conducted on the odds ratio (OR) scale using a weakly informative prior. The probabilities of any benefit (i.e. OR < 1) and that the number needed to treat (NNT) was 5%) were computed from the posterior. The 95% predictive interval (95% PI) was computed, which corresponds to the predicted range of the effect estimate of a future RCT. Results: Two RCTs at low risk of bias were included, which comprised 102 patients. The pooled OR was 0.61 [95% credible interval (95% CrI) = 0.27–1.40], which corresponded to a probability of any benefit with vancomycin prophylaxis of 88.0% and a probability that the NNT was <20 of 75.9%. The 95% PI was 0.19–2.00. Conclusions: Based on two small RCTs, there is a reasonable probability that secondary vancomycin prophylaxis during antibiotic re-exposure reduces 56-day rCDI. However, these results remain uncertain as the 95% PI is wide and consequently larger trials are needed.
- 2 July 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (4)
Open AccessSecondary vancomycin prophylaxis during antibiotic re-exposure for the prevention of recurrent Clostridioides difficile infections: a systematic review and Bayesian meta-analysis
Background: Antibiotic re-exposure after an episode of Clostridioides difficile infection (CDI) is common and is a strong risk factor for recurrent CDI (rCDI). Two randomized controlled trials (RCTs) of vancomycin prophylaxis during antibiotic re-exposure were recently published, which we sought to evaluate by meta-analysis. Methods: We updated a recent systematic review search of MEDLINE and Embase via Ovid to 9 March 2026. RCTs of vancomycin during antibiotic re-exposure as secondary CDI prophylaxis were included. Quality was assessed by the Cochrane RoB2 tool. A Bayesian meta-analysis of 56-day rCDI was conducted on the odds ratio (OR) scale using a weakly informative prior. The probabilities of any benefit (i.e. OR < 1) and that the number needed to treat (NNT) was 5%) were computed from the posterior. The 95% predictive interval (95% PI) was computed, which corresponds to the predicted range of the effect estimate of a future RCT. Results: Two RCTs at low risk of bias were included, which comprised 102 patients. The pooled OR was 0.61 [95% credible interval (95% CrI) = 0.27–1.40], which corresponded to a probability of any benefit with vancomycin prophylaxis of 88.0% and a probability that the NNT was <20 of 75.9%. The 95% PI was 0.19–2.00. Conclusions: Based on two small RCTs, there is a reasonable probability that secondary vancomycin prophylaxis during antibiotic re-exposure reduces 56-day rCDI. However, these results remain uncertain as the 95% PI is wide and consequently larger trials are needed.
- 27 March 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 11 (1) , 37-50
Diagnosis, treatment, and prophylaxis of Clostridioides difficile infections: A cross-sectional survey of Canadian clinicians
Background: A recent international survey of clinician practices in the management of Clostridioides difficile infections (CDIs) identified numerous areas of practice heterogeneity. The degree of practice variability within Canada is unknown. Methods: Data from Canadian participants of an international survey of clinician CDI practices were extracted. Practice alignment with the Association of Medical Microbiology and Infectious Disease (AMMI) Canada CDI treatment guidelines was assessed. CDI practices were compared across provinces using the Fisher exact test with a simulated P value. Results: A total of 112 responses were obtained from eight provinces. Vancomycin (85.3% for first episode), vancomycin pulse and taper (P-T) (61.8% and 32.4% for first and second recurrences, respectively), and fecal microbiota transplant (32.4% for third recurrence) were preferred treatment strategies. Practice alignment with the AMMI Canada CDI guidelines for the treatment of recurrences was low (range 23.5%–32.4%, depending on the recurrence number). With respect to secondary CDI prophylaxis during antibiotic reexposure, there were interprovincial differences in the perceived indication ( P = .03), whether to prescribe at all ( P < .001), and duration of prophylaxis ( P = .004). There was significant clinician support (>50%) for randomized clinical trials testing treatment strategies for recurrent episodes and for secondary prophylaxis. Conclusion: Despite the availability of national guidelines, we found significant heterogeneity in practice across Canada, often not aligned with guideline recommendations. These findings underscore the need for a platform trial comparing treatment strategies and a trial to establish the efficacy of secondary prophylaxis.
- 27 March 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 11 (1) , 37-50
Diagnosis, treatment, and prophylaxis of Clostridioides difficile infections: A cross-sectional survey of Canadian clinicians
Background: A recent international survey of clinician practices in the management of Clostridioides difficile infections (CDIs) identified numerous areas of practice heterogeneity. The degree of practice variability within Canada is unknown. Methods: Data from Canadian participants of an international survey of clinician CDI practices were extracted. Practice alignment with the Association of Medical Microbiology and Infectious Disease (AMMI) Canada CDI treatment guidelines was assessed. CDI practices were compared across provinces using the Fisher exact test with a simulated P value. Results: A total of 112 responses were obtained from eight provinces. Vancomycin (85.3% for first episode), vancomycin pulse and taper (P-T) (61.8% and 32.4% for first and second recurrences, respectively), and fecal microbiota transplant (32.4% for third recurrence) were preferred treatment strategies. Practice alignment with the AMMI Canada CDI guidelines for the treatment of recurrences was low (range 23.5%–32.4%, depending on the recurrence number). With respect to secondary CDI prophylaxis during antibiotic reexposure, there were interprovincial differences in the perceived indication ( P = .03), whether to prescribe at all ( P < .001), and duration of prophylaxis ( P = .004). There was significant clinician support (>50%) for randomized clinical trials testing treatment strategies for recurrent episodes and for secondary prophylaxis. Conclusion: Despite the availability of national guidelines, we found significant heterogeneity in practice across Canada, often not aligned with guideline recommendations. These findings underscore the need for a platform trial comparing treatment strategies and a trial to establish the efficacy of secondary prophylaxis.
- Open Access
- 12 February 2026
- Published by Wiley
Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study
Introduction The 2020 Protection of Students with Life-Threatening Allergies Act, obligates schools across Alberta, Canada to hold a common use stock of at least one epinephrine autoinjector (EAI) and to maintain a protocol for the prevention and management of anaphylaxis Herein, we assessed the effectiveness of this policy by comparing pre-hospital EAI use before and after implementation of the act. Methods The Cross-Canada Anaphylaxis Registry (C-CARE) enrolls patients presenting to a participating emergency department with anaphylaxis defined as the involvement of ≥2 systems and/or hypotension. Specific to this project, we extracted data on pediatric patients recruited from the Stollery Children’s Hospital in Edmonton, Alberta from 2016-2024. Data were collected on demographics, comorbidities, symptomatology, pre- and intra-hospital management, and outcome of anaphylaxis by standardized chart review. Multivariable logistic regression was used to assess pre-hospital EAI use for cases occurring at school before versus after the enactment of the Act on January 1, 2020. Evaluating pre-hospital EAI use in Quebec and Ontario and antihistamine use pre versus post act in Alberta were used as negative controls. Result Of the 59 cases of in-school anaphylaxis identified over the study period, 52.5% occurred post-Act. The median age was 13.0 years (IQR=9.5-15.8) and 40.7% were male. EAI use in schools was greater post-act versus pre-act (64.5% versus 35.7%, aOR=3.82, 95%CI=1.24-11.7). There was no difference in pre-hospital EAI use pre versus post 2020 in Quebec and Ontario, that did not use the act (aOR=0.72, 95%CI=0.31-1.70). There was no difference in pre-hospital antihistamine use pre versus post act (aOR=0.31, 95%CI=0.07-1.41). Conclusion Implementation of the provincial policy was associated with an increase in pre-hospital EAI use in cases of pediatric anaphylaxis occurring at school. These preliminary results support the effectiveness of policy interventions for anaphylaxis management.
- 12 February 2026
- Published by Wiley
Open AccessEffectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study
Introduction The 2020 Protection of Students with Life-Threatening Allergies Act, obligates schools across Alberta, Canada to hold a common use stock of at least one epinephrine autoinjector (EAI) and to maintain a protocol for the prevention and management of anaphylaxis Herein, we assessed the effectiveness of this policy by comparing pre-hospital EAI use before and after implementation of the act. Methods The Cross-Canada Anaphylaxis Registry (C-CARE) enrolls patients presenting to a participating emergency department with anaphylaxis defined as the involvement of ≥2 systems and/or hypotension. Specific to this project, we extracted data on pediatric patients recruited from the Stollery Children’s Hospital in Edmonton, Alberta from 2016-2024. Data were collected on demographics, comorbidities, symptomatology, pre- and intra-hospital management, and outcome of anaphylaxis by standardized chart review. Multivariable logistic regression was used to assess pre-hospital EAI use for cases occurring at school before versus after the enactment of the Act on January 1, 2020. Evaluating pre-hospital EAI use in Quebec and Ontario and antihistamine use pre versus post act in Alberta were used as negative controls. Result Of the 59 cases of in-school anaphylaxis identified over the study period, 52.5% occurred post-Act. The median age was 13.0 years (IQR=9.5-15.8) and 40.7% were male. EAI use in schools was greater post-act versus pre-act (64.5% versus 35.7%, aOR=3.82, 95%CI=1.24-11.7). There was no difference in pre-hospital EAI use pre versus post 2020 in Quebec and Ontario, that did not use the act (aOR=0.72, 95%CI=0.31-1.70). There was no difference in pre-hospital antihistamine use pre versus post act (aOR=0.31, 95%CI=0.07-1.41). Conclusion Implementation of the provincial policy was associated with an increase in pre-hospital EAI use in cases of pediatric anaphylaxis occurring at school. These preliminary results support the effectiveness of policy interventions for anaphylaxis management.
- Open Access
Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry
Background: Mastocytosis is a rare hematologic disorder, classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Understanding age-related differences in presentation and management is essential for individualized care. Methods: Data from patients recruited from the Montreal Children’s and Montreal General Hospitals between 2015 and 2024 were analyzed. Descriptive statistics were employed to present patient demographics, clinical characteristics, and medication usage. Statistical analyses included Fisher’s exact test for categorical variables and t-tests or non-parametric equivalents for continuous variables. Results: A total of 63 patients were included, comprising 39 children and 24 adults. Children had a median age of 1.9 years, while adults had a median age of 49.3 years. CM was exclusively prevalent in children (100.0%), while SM was more common in adults (45.8%). Adults with SM had a significantly higher median age than CM (49.4 versus 44.7 years, respectively, p = 0.03). Epinephrine use was more frequent in adult SM patients (36.4% versus 0%, respectively, p = 0.03). No pediatric patients required epinephrine for symptom control. Conclusions: This study highlights important clinical differences between pediatric and adult mastocytosis. CM was more common in children while SM predominated in adults and was associated with greater flare severity and higher tryptase levels.
Open AccessComparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry
Background: Mastocytosis is a rare hematologic disorder, classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Understanding age-related differences in presentation and management is essential for individualized care. Methods: Data from patients recruited from the Montreal Children’s and Montreal General Hospitals between 2015 and 2024 were analyzed. Descriptive statistics were employed to present patient demographics, clinical characteristics, and medication usage. Statistical analyses included Fisher’s exact test for categorical variables and t-tests or non-parametric equivalents for continuous variables. Results: A total of 63 patients were included, comprising 39 children and 24 adults. Children had a median age of 1.9 years, while adults had a median age of 49.3 years. CM was exclusively prevalent in children (100.0%), while SM was more common in adults (45.8%). Adults with SM had a significantly higher median age than CM (49.4 versus 44.7 years, respectively, p = 0.03). Epinephrine use was more frequent in adult SM patients (36.4% versus 0%, respectively, p = 0.03). No pediatric patients required epinephrine for symptom control. Conclusions: This study highlights important clinical differences between pediatric and adult mastocytosis. CM was more common in children while SM predominated in adults and was associated with greater flare severity and higher tryptase levels.
- Open Access
- 26 June 2025
- Published by Elsevier in CMI Communications
- Vol. 2 (3)
Standing on the shoulders of imperfect humans: Adjunctive therapy for Enterococcus faecalis infective endocarditis
- 26 June 2025
- Published by Elsevier in CMI Communications
- Vol. 2 (3)
Open AccessStanding on the shoulders of imperfect humans: Adjunctive therapy for Enterococcus faecalis infective endocarditis
- 26 May 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (1) , 88-89
Paradoxical Eczema Associated With Biologic Therapy in Psoriasis: A Systematic Review and Meta-Analysis
- 26 May 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (1) , 88-89
Paradoxical Eczema Associated With Biologic Therapy in Psoriasis: A Systematic Review and Meta-Analysis